Clinical Trials Remain Underway for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
July 30th 2020Ian E. Krop, MD, PhD, discusses the importance of clinical trials further exploring the role of trastuzumab deruxtecan following the FDA’s approval of the agent as treatment of patients with HER2-positive metastatic breast cancer.
Watch
Real-World Comparison Assesses Mobocertinib in NSCLC With EGFR Exon 20
July 29th 2020Leora Horn, MD, MSc, discusses the real-world data outcomes compared with clinical trial data of mobocertinib from a retrospective study in patients with refractory non–small cell lung cancer with EGFR exon 20 insertions.
Watch
Advancing Survival in Relapsed/Refractory Multiple Myeloma
July 28th 2020A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.
Watch
Interim Analysis Demonstrates Reassuring Toxicity Profile for Glioblastoma
July 24th 2020David Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.
Watch